Edition:
United Kingdom

Dr.Reddy's Laboratories Ltd (REDY.NS)

REDY.NS on National Stock Exchange of India

2,613.15INR
11:21am BST
Change (% chg)

Rs-42.40 (-1.60%)
Prev Close
Rs2,655.55
Open
Rs2,659.95
Day's High
Rs2,680.00
Day's Low
Rs2,604.05
Volume
468,248
Avg. Vol
681,778
52-wk High
Rs2,964.00
52-wk Low
Rs1,872.95

Latest Key Developments (Source: Significant Developments)

Dr.Reddy's Laboratories Says FDA Issued Form 483 With 5 Observations For Hyderabad Plant
Friday, 12 Jul 2019 

July 12 (Reuters) - Dr.Reddy's Laboratories Ltd ::SAYS AUDIT AT API MANUFACTURING PLANT 2 AT BOLLARAM, HYDERABAD BY THE US FDA, HAS BEEN COMPLETED.SAYS USFDA ISSUED A FORM 483 WITH 5 OBSERVATIONS FOR HYDERABAD PLANT .  Full Article

Dr.Reddy's Labs Launches Over-the-counter Mucinex D Tablets In U.S.
Tuesday, 9 Jul 2019 

July 9 (Reuters) - Dr.Reddy's Laboratories Ltd ::LAUNCHES OVER-THECOUNTER STORE BRAND EQUIVALENT OF MUCINEX D EXTENDED RELEASE TABLETS IN THE U.S. MARKET.  Full Article

Dr.Reddy's Laboratories Launches Carboprost Tromethamine Injection USP In U.S.
Wednesday, 3 Jul 2019 

July 3 (Reuters) - Dr.Reddy's Laboratories Ltd ::LAUNCHES CARBOPROST TROMETHAMINE INJECTION USP, 250 MCG/ML (1ML) SINGLE-DOSE VIAL IN U.S..  Full Article

Dr.Reddy's Launches Tobramycin Inhalation Solution In U.S.
Tuesday, 25 Jun 2019 

June 25 (Reuters) - Dr.Reddy's Laboratories Ltd ::ANNOUNCES THE LAUNCH OF TOBRAMYCIN INHALATION SOLUTION, USP IN THE U.S. MARKET.  Full Article

U.S. Appeals Court Rules In Favor Of Lilly In Alimta Vitamin Regimen Patent Lawsuit
Friday, 26 Apr 2019 

April 26 (Reuters) - Eli Lilly and Co ::U.S. COURT OF APPEALS RULES IN FAVOR OF LILLY IN ALIMTA VITAMIN REGIMEN PATENT LAWSUIT.ELI LILLY AND CO - IF PATENT IS ULTIMATELY UPHELD THROUGH ALL REMAINING CHALLENGES, ALIMTA WOULD MAINTAIN U.S. EXCLUSIVITY UNTIL MAY 2022.ELI LILLY - U.S. COURT OF APPEALS DECISION UPHOLDS AN OCTOBER 2017 DECISION BY PATENT TRIAL AND APPEAL BOARD OF U.S. PATENT AND TRADEMARK OFFICE.ELI LILLY AND CO - DR. REDDY'S LABORATORIES AND HOSPIRA HAVE APPEALED DISTRICT COURT'S DECISIONS.ELI LILLY AND CO - HEARING ON THOSE APPEALS IS SCHEDULED FOR JUNE 2019..  Full Article

Dr.Reddy's Laboratories Gets Approval For Clopidogrel In China
Thursday, 25 Apr 2019 

April 25 (Reuters) - Dr.Reddy's Laboratories Ltd ::HAS RECEIVED APPROVAL FOR THE PRODUCT CLOPIDOGREL IN CHINA.SAYS SALES FROM ANTI-BLOOD CLOTTING DRUG WILL NOT BE MATERIAL IN FY2020.  Full Article

Dr.Reddy's Laboratories Says Duvvada Facility Re-inspected By Regulatory Authority Of Germany & Considered To Be Fully Compliant
Friday, 29 Mar 2019 

March 29 (Reuters) - Dr.Reddy's Laboratories Ltd ::FORMULATIONS MANUFACTURING FACILITY IN DUVVADA RE-INSPECTED BY REGULATORY AUTHORITY OF GERMANY & CONSIDERED TO BE FULLY COMPLIANT.  Full Article

Dr.Reddy's Says USFDA Audit Of Shreveport Plant Completed With Zero Observations
Friday, 22 Feb 2019 

Feb 22 (Reuters) - Dr.Reddy's Laboratories Ltd ::AUDIT OF FORMULATIONS SHREVEPORT PLANT, LOUISIANA, USA, BY US FDA, HAS BEEN COMPLETED WITH ZERO OBSERVATIONS.  Full Article

Indivior Launches Generic Version Of Its Suboxone Film
Wednesday, 20 Feb 2019 

Feb 20 (Reuters) - Indivior PLC ::INDIVIOR LAUNCHES SUBOXONE FILM AUTHORIZED GENERIC.U.S. AFFILIATE, INDIVIOR INC HAS LAUNCHED AN AUTHORIZED GENERIC VERSION OF SUBOXONE FILM (CIII) IN U.S.AUTHORIZED GENERIC IS BEING MARKETED AND DISTRIBUTED ON INDIVIOR'S BEHALF BY SANDOZ INC.DECISION TO LAUNCH SUBOXONE GENERIC BASED ON MARKET IMPACT EXPECTED FROM ANTICIPATED "AT RISK" LAUNCH OF GENERIC DR. REDDY'S AND/OR ALVOGEN.  Full Article

Indivior Says Court Denied Its Motion To Prevent Sale Of Suboxone Copycats
Tuesday, 12 Feb 2019 

Feb 12 (Reuters) - Indivior PLC ::FEDERAL COURT DENIES MOTION TO STAY.COURT OF APPEALS FOR FEDERAL CIRCUIT DENIES MOTION TO STAY ISSUANCE OF MANDATE.FILED EMERGENCY MOTION TO STAY MANDATE PENDING RESOLUTION OF ITS FORTHCOMING APPLICATION FOR AN ADMINISTRATIVE STAY TO SUPREME COURT OF US.AFTER MANDATE ISSUES, REDDY'S, ALVOGEN WILL NO LONGER BE PREVENTED FROM SELLING OR IMPORTING GENERIC BUPRENORPHINE/NALOXONE SUBLINGUAL FILM.COURT DENIED CO'S MOTION TO STAY ISSUANCE OF MANDATE FOLLOWING CAFC'S RULING VACATING PRELIMINARY INJUNCTION AGAINST DR. REDDY'S.  Full Article

UPDATE 2-U.S. FDA says Indian drugmaker was shredding, dumping key documents

BENGALURU, July 17 A U.S. Food and Drug Administration (FDA) investigator discovered that India's Strides Pharma Science Ltd, which exports to the U.S. market, was shredding drug production, quality and laboratory documents and dumping others in a scrap yard.